Switching between P2Y12 antagonists - From bench to bedside.

[1]  Deepak L. Bhatt,et al.  Practical considerations for cangrelor use in patients with acute coronary syndromes , 2019, European heart journal. Acute cardiovascular care.

[2]  A. Alexandrov,et al.  Ticagrelor for stroke prevention in patients with vascular risk factors: A systematic review and meta-analysis , 2018, Journal of the Neurological Sciences.

[3]  J. Siller-Matula,et al.  Ticagrelor – toward more efficient platelet inhibition and beyond , 2018, Therapeutics and clinical risk management.

[4]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[5]  Deepak L. Bhatt,et al.  International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies , 2017, Circulation.

[6]  P. Morange,et al.  Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study , 2017, European heart journal.

[7]  M. Hadamitzky,et al.  Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial , 2017, The Lancet.

[8]  G. Lippi,et al.  Worldwide epidemiology and trends of adenosine diphosphate (ADP) receptor inhibitors usage , 2017 .

[9]  J. Nawarskas,et al.  Cangrelor: A New Route for P2Y12 Inhibition , 2017, Cardiology in review.

[10]  Deepak L. Bhatt,et al.  Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital. , 2017, Journal of the American College of Cardiology.

[11]  C. Hesse,et al.  Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery , 2016, European Journal of Cardio-Thoracic Surgery.

[12]  G. Wells,et al.  A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome , 2016, Thrombosis and Haemostasis.

[13]  J. Horáček,et al.  High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction , 2016, Anatolian journal of cardiology.

[14]  A. Khan,et al.  Stent Thrombosis Secondary to Ticagrelor Resistance as Demonstrated by Thromboelastography , 2016 .

[15]  Joo-In Park,et al.  Platelet Activation: The Mechanisms and Potential Biomarkers , 2016, BioMed research international.

[16]  L. Been,et al.  Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study. , 2016, JACC. Cardiovascular interventions.

[17]  Yoshio Kobayashi,et al.  Repetitive stent thrombosis in a patient who had resistance to both clopidogrel and prasugrel. , 2016, Journal of cardiology cases.

[18]  R. Schulz,et al.  Effects of P2Y12 receptor antagonists beyond platelet inhibition – comparison of ticagrelor with thienopyridines , 2016, British journal of pharmacology.

[19]  K. Anstrom,et al.  In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study , 2015, European heart journal. Acute cardiovascular care.

[20]  C. Gachet,et al.  Purinergic Receptors in Thrombosis and Inflammation , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[21]  M. Marszałł,et al.  Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial , 2015, European heart journal.

[22]  H. Crijns,et al.  Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication , 2015, Haematologica.

[23]  R. Teng.  Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update , 2015, Clinical Pharmacokinetics.

[24]  H. Ince,et al.  MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel – the European MULTIPRAC Registry , 2015, European heart journal. Acute cardiovascular care.

[25]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[26]  A. Roguin,et al.  Stent thrombosis in a patient with high on-treatment platelet reactivity despite ticagrelor treatment , 2015, European heart journal. Acute cardiovascular care.

[27]  K. Huber,et al.  How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer? , 2015, Thrombosis and Haemostasis.

[28]  D. Schneider,et al.  Pharmacodynamic effects during the transition between cangrelor and prasugrel , 2015, Coronary artery disease.

[29]  Deepak L. Bhatt,et al.  In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights Into Contemporary Practice From the National Cardiovascular Data Registry , 2014, Circulation. Cardiovascular interventions.

[30]  M. Effron,et al.  Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). , 2014, Journal of the American College of Cardiology.

[31]  L. Maillard,et al.  Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. , 2014, International journal of cardiology.

[32]  D. Schneider,et al.  Pharmacodynamic effects during the transition between cangrelor and ticagrelor. , 2014, JACC. Cardiovascular interventions.

[33]  C. Indolfi,et al.  Administration of a Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch From Ongoing Clopidogrel Treatment to Ticagrelor in Patients With Acute Coronary Syndrome , 2014, Circulation. Cardiovascular interventions.

[34]  J. Sidaway,et al.  Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1 , 2014, Journal of cardiovascular pharmacology and therapeutics.

[35]  S. Krähenbühl,et al.  Clinical implications of drug–drug interactions with P2Y12 receptor inhibitors , 2014, Journal of thrombosis and haemostasis : JTH.

[36]  Yachen Zhang,et al.  High-Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis , 2013, PloS one.

[37]  D. Danielak,et al.  Clinical Pharmacokinetics of Clopidogrel and Its Metabolites in Patients with Cardiovascular Diseases , 2013, Clinical Pharmacokinetics.

[38]  A. Corsini,et al.  Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties , 2013, Drugs.

[39]  M. Effron,et al.  Effect on Platelet Reactivity From a Prasugrel Loading Dose After a Clopidogrel Loading Dose Compared With a Prasugrel Loading Dose Alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): A Randomized Controlled Trial , 2013, Circulation. Cardiovascular interventions.

[40]  E. Vicaut,et al.  Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. , 2013, The New England journal of medicine.

[41]  Gregg W Stone,et al.  Effect of platelet inhibition with cangrelor during PCI on ischemic events. , 2013, The New England journal of medicine.

[42]  Deepak L. Bhatt,et al.  Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. , 2012, The New England journal of medicine.

[43]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[44]  C. Gachet.  P2Y12 receptors in platelets and other hematopoietic and non-hematopoietic cells , 2012, Purinergic Signalling.

[45]  M. Price,et al.  Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. , 2012, JAMA.

[46]  B. Yan,et al.  Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? , 2011, British journal of clinical pharmacology.

[47]  G. Stone,et al.  How to minimize stent thrombosis. , 2011, Circulation.

[48]  D. Atar,et al.  Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. , 2011, European heart journal.

[49]  T. Costigan,et al.  Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. , 2010, Journal of the American College of Cardiology.

[50]  J. Eikelboom,et al.  Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study , 2010, Circulation.

[51]  Mark J. Antonino,et al.  Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study , 2009, Circulation.

[52]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[53]  L. Wallentin.  P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. , 2009, European heart journal.

[54]  S. Heptinstall,et al.  The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function , 2008, Journal of thrombosis and haemostasis : JTH.

[55]  E. Antman,et al.  Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial , 2007, Circulation.

[56]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[57]  M. Gawaz,et al.  The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score , 2007, Journal of thrombosis and haemostasis : JTH.

[58]  M. Forrester.  Pattern of clopidogrel exposures reported to Texas poison centers during 1998–2004 , 2007, Clinical toxicology.

[59]  J. Herbert,et al.  Identification and Biological Activity of the Active Metabolite of Clopidogrel , 2000, Thrombosis and Haemostasis.

[60]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[61]  K. Anstrom,et al.  Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE‐ACS) obse , 2017, American heart journal.

[62]  D. Angiolillo,et al.  Switching P2Y12-receptor inhibitors in patients with coronary artery disease , 2016, Nature Reviews Cardiology.

[63]  C. Stefanadis,et al.  In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. , 2014, American heart journal.

[64]  D. Sibbing,et al.  Thienopyridines and other ADP-receptor antagonists. , 2012, Handbook of experimental pharmacology.

[65]  M. Ranucci,et al.  Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. , 2011, The Annals of thoracic surgery.

[66]  S. Steinhubl,et al.  Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. , 2008, Thrombosis research.

[67]  K. Jurk,et al.  Platelets: Physiology and Biochemistry , 2005, Seminars in thrombosis and hemostasis.